Some patients may need several acute medication options to address their varying migraine pain and associated symptoms. In a survey conducted at three headache centers in the U.S. and Sweden (n=183), 37% of patients weren’t satisfied with the speed of effect from their current migraine therapy (96.4% were current triptan users).1
Zembrace® SymTouch® is a ready-to-use, single-use, 3 mg sumatriptan auto-injector
Zembrace® SymTouch® may be an appropriate option for patients experiencing:2
Do not use Zembrace® SymTouch® in patients with ischemic or vasospastic coronary artery disease, Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders, or a history of stroke or transient ischemic attacks. These are not all of the contraindications for Zembrace® SymTouch®.
- Bigal M, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007;47(4):475-479.
- Rothrock JF, Friedman DI. Information for health care professionals: triptan therapy for acute migraine. American
Headache Society website. https://americanheadachesociety.org/wp-content/uploads/2018/05/John_Rothrock_and_Deborah_Friedman_-_Triptans.pdf. Published July 2016. Accessed December 11, 2019.